Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
STOK

STOK - Stoke Therapeutics Inc Stock Price, Fair Value and News

16.26USD-1.26 (-7.19%)Market Closed

Market Summary

STOK
USD16.26-1.26
Market Closed
-7.19%

STOK Alerts

  • 4 major insider sales recently.

STOK Stock Price

View Fullscreen

STOK RSI Chart

STOK Valuation

Market Cap

913.1M

Price/Earnings (Trailing)

-8.41

Price/Sales (Trailing)

104

Price/Free Cashflow

-10.65

STOK Price/Sales (Trailing)

STOK Profitability

Return on Equity

-77.33%

Return on Assets

-52.89%

Free Cashflow Yield

-9.39%

STOK Fundamentals

STOK Revenue

Revenue (TTM)

8.8M

Rev. Growth (Yr)

-18.17%

Rev. Growth (Qtr)

50.46%

STOK Earnings

Earnings (TTM)

-108.5M

Earnings Growth (Yr)

-16.98%

Earnings Growth (Qtr)

2.17%

Breaking Down STOK Revenue

Last 7 days

15.2%

Last 30 days

36.9%

Last 90 days

174.2%

Trailing 12 Months

39.8%

How does STOK drawdown profile look like?

STOK Financial Health

Current Ratio

5.43

STOK Investor Care

Shares Dilution (1Y)

17.95%

Diluted EPS (TTM)

-2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202314.6M12.6M10.7M8.8M
202200012.4M

Tracking the Latest Insider Buys and Sells of Stoke Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
ticho barry
acquired
6,000
0.6
10,000
chief medical officer
Jun 03, 2024
ticho barry
sold
-152,185
15.2185
-10,000
chief medical officer
May 20, 2024
nash huw m.
sold
-769,500
15.39
-50,000
coo & cbo
May 20, 2024
kaye edward m. md
sold
-653,529
15.4316
-42,350
ceo
May 20, 2024
nash huw m.
acquired
20,000
0.4
50,000
coo & cbo
May 20, 2024
allan jonathan
acquired
60,794
7.07
8,599
general counsel & corp sec
May 20, 2024
allan jonathan
sold
-129,327
15.0398
-8,599
general counsel & corp sec
May 01, 2024
ticho barry
acquired
6,000
0.6
10,000
chief medical officer
May 01, 2024
ticho barry
sold
-113,653
11.3653
-10,000
chief medical officer
Apr 17, 2024
skorpios trust
sold
-41,760,000
11.6
-3,600,000
-

1–10 of 50

Which funds bought or sold STOK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Ikarian Capital, LLC
reduced
-43.74
28,286
92,017
0.01%
May 17, 2024
Artal Group S.A.
new
-
4,050,000
4,050,000
0.10%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.26
13,961
37,841
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-71.7
-73,085
194,049
-%
May 15, 2024
Lynx1 Capital Management LP
added
25.02
34,353,700
49,907,100
12.85%
May 15, 2024
DEUTSCHE BANK AG\
reduced
-0.13
3,394,030
5,565,240
-%
May 15, 2024
STATE STREET CORP
added
6.64
4,965,710
7,824,700
-%
May 15, 2024
Tudor Investment Corp Et Al
new
-
449,901
449,901
-%
May 15, 2024
GILDER GAGNON HOWE & CO LLC
added
44.23
884,647
1,212,070
0.01%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
1,935,240
1,935,240
-%

1–10 of 47

Are Funds Buying or Selling STOK?

Are funds buying STOK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own STOK
No. of Funds

Unveiling Stoke Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 18, 2024
skorpios trust
-
6,905,121
SC 13D/A
Feb 26, 2024
cowen financial products llc
5.77%
2,276,106
SC 13G
Feb 26, 2024
cowen financial products llc
8.3%
3,721,659
SC 13G/A
Feb 14, 2024
lynx1 capital management lp
6.6%
2,956,918
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.3%
4,131,045
SC 13G/A
Feb 14, 2024
redmile group, llc
5.9%
2,625,506
SC 13G/A
Feb 09, 2024
morgan stanley
7.5%
3,358,375
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Nov 06, 2023
lynx1 capital management lp
6.0%
2,664,158
SC 13G
Feb 14, 2023
rtw investments, lp
9.8%
3,870,981
SC 13G/A

Recent SEC filings of Stoke Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
S-3
S-3
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading

Peers (Alternatives to Stoke Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Stoke Therapeutics Inc News

Latest updates
MarketBeat4 hours ago

Stoke Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q1
Revenue50.5%4.003.003.004.005.003.003.003.003.00
Operating Expenses0.6%33.0032.0031.0031.0030.0030.0030.0028.0028.00
  S&GA Expenses-3.7%10.0011.0010.0010.0010.009.0010.0010.009.00
  R&D Expenses2.7%22.0022.0020.0021.0020.0021.0020.0018.0018.00
Net Income2.2%-26.37-26.96-24.54-30.65-22.54-25.65-26.11-24.65-24.65
Net Income Margin-3.7%-12.36*-11.92*-9.66*-8.31*-6.80*-8.15*---
Free Cashflow-17.7%-24.58-20.88-17.64-22.64-21.52-22.78-24.09-20.6132.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-10.1%205228240257282256278301316239254264279298200210221229239246108
  Current Assets-10.2%193215230246270244265289306229245260275294195206216226237244106
    Cash Equivalents-6.7%17919119019219011411368.0084.00145149169268287191202211222233243105
  Net PPE-9.4%5.006.006.006.007.007.007.006.005.004.003.003.003.003.003.003.003.003.002.002.001.00
Liabilities-5.7%65.0069.0067.0067.0068.0071.0073.0077.0076.0021.0016.009.006.0012.007.007.006.004.005.005.002.00
  Current Liabilities15.5%36.0031.0025.0022.0032.0031.0029.0028.0023.0017.0012.008.006.0011.007.006.005.004.005.005.002.00
Shareholder's Equity-12.0%140160173190214185204224240218238255272286193203214224234242105
  Retained Earnings-6.6%-428-401-374-350-319-297-271-245-220-196-171-149-127-110-95.72-82.03-69.07-58.03-47.87-39.27-25.71
  Additional Paid-In Capital1.3%569561548541534483477471461414409404400396288285283282282281131
Shares Outstanding1.3%46.0046.0044.0044.0043.0039.0039.0038.0037.0037.0037.0037.00---------
Float----290---297---665---385---490-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-19.0%-24,566-20,649-17,262-21,800-21,356-22,373-22,056-19,92832,491-16,258-14,682-15,831-20,136-10,931-10,873-9,646-10,771-10,201-8,048-6,274-6,532
  Share Based Compensation-10.7%5,4106,0586,5526,7605,8875,7905,9266,1634,9754,6864,6144,4522,6981,5801,7851,649754712731298181
Cashflow From Investing-32.4%9,98814,77114,61723,47353,08522,49067,264146-135,78211,797-5,264-82,755-204-90.00-269-81.00-610-569-583-392-90.00
Cashflow From Financing-76.6%1,7177,34356248.0045,05443.004343,42542,507171408159546106,868673369198192-1,000150,638-68.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

STOK Income Statement

2024-03-31
Consolidated statements of operations and comprehensive loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 4,216$ 5,152
Operating expenses:  
Research and development22,36819,631
General and administrative10,22010,211
Total operating expenses32,58829,842
Loss from operations(28,372)(24,690)
Other income (expense):  
Interest income (expense), net2,4262,103
Other income (expense), net(428)42
Total other income (expense)1,9982,145
Net loss$ (26,374)$ (22,545)
Net loss per share, basic$ (0.57)$ (0.53)
Net loss per share, diluted$ (0.57)$ (0.53)
Weighted-average common shares outstanding, basic46,246,88942,536,474
Weighted-average common shares outstanding, diluted46,246,88942,536,474
Comprehensive loss:  
Net Income (Loss)$ (26,374)$ (22,545)
Other comprehensive gain (loss):  
Unrealized gain (loss) on marketable securities24577
Total other comprehensive gain24577
Comprehensive loss$ (26,350)$ (21,968)

STOK Balance Sheet

2024-03-31
Consolidated balance sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 178,581$ 191,442
Marketable securities 9,952
Prepaid expenses10,72211,320
Other current assets3,5592,561
Deferred financing costs402 
Interest receivable1164
Total current assets193,275215,339
Restricted cash569569
Operating lease right-of-use assets6,0606,611
Property and equipment, net5,2785,823
Total Assets205,182228,342
Current liabilities:  
Accounts payable2,1021,695
Accrued and other current liabilities12,57013,815
Deferred revenue - current portion20,91815,309
Total current liabilities35,59030,819
Deferred revenue - net of current portion25,04233,074
Other long term liabilities4,2084,884
Total long term liabilities29,25037,958
Total liabilities64,84068,777
Commitments and contingencies (Note 6)
Stockholders’ equity  
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 46,498,077 and 45,918,233 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively55
Additional paid-in capital568,560561,433
Accumulated other comprehensive loss (24)
Accumulated deficit(428,223)(401,849)
Total stockholders’ equity140,342159,565
Total liabilities and stockholders’ equity$ 205,182$ 228,342
STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
 CEO
 WEBSITEstoketherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES117

Stoke Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Stoke Therapeutics Inc? What does STOK stand for in stocks?

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stoke Therapeutics Inc (STOK)?

As of Thu Jun 13 2024, market cap of Stoke Therapeutics Inc is 913.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers. The fair value of Stoke Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stoke Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stoke Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

What is Stoke Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, STOK's PE ratio (Price to Earnings) is -8.41 and Price to Sales (PS) ratio is 104. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.